Welcome to our dedicated page for Nanovibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on Nanovibronix stock.
This page provides a historical news feed for NanoVibronix, Inc. under the ticker NAOV, which later changed its corporate name to ENvue Medical, Inc. and its Nasdaq ticker to FEED. The archived coverage reflects the company’s evolution as a medical technology business focused on non-invasive therapeutic systems and minimally invasive navigation platforms for enteral care and related clinical applications.
News items associated with NAOV include announcements about the company’s acoustic-based therapeutic technologies, such as PainShield and UroShield, which use proprietary low-intensity surface acoustic wave technology and are intended to treat pain, reduce bacterial colonization, and disrupt biofilms in home or care settings. Releases also describe developments around the UroShield Kit, including its addition to the UK National Health Service Drug Tariff Part IX and the resulting prescription reimbursement pathway across the UK.
Another major theme in the NAOV news history is the integration and expansion of the ENvue Navigation Platform, a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. Company communications highlight FDA 510(k) clearance for adult use, real-time bedside visualization of tube movement, and plans to build a broader enteral-feeding ecosystem around this platform. Additional stories cover training initiatives, such as the Oscar training aid for naso-enteral feeding procedures, and intellectual property developments related to navigation technology.
Investors and observers can use this NAOV news archive to trace key milestones such as the strategic shift toward enteral navigation, financing transactions disclosed in press releases, and the formal rebranding to ENvue Medical, Inc. For the most recent developments after the name and ticker change, subsequent news is released under the FEED symbol.
NanoVibronix, Inc. (NASDAQ: NAOV) has successfully closed its public offering of 4,531,434 shares at $0.75 per share, resulting in gross proceeds of approximately $3.4 million. The offering included the underwriter's exercised option for an additional 198,100 shares. The funds will support working capital and facilitate transitioning manufacturing from China to the United States. H.C. Wainwright & Co. was the book-running manager for this transaction, which was conducted under an effective shelf registration statement.
NanoVibronix, Inc. (NASDAQ: NAOV) announced an increase in its public offering to 4,333,334 shares at $0.75 each due to high demand, with expected gross proceeds of approximately $3.25 million. The offering's closing is set for August 27, 2020, pending customary conditions. The underwriter, H.C. Wainwright & Co., holds a 30-day option for an additional 650,000 shares. Proceeds will support working capital and transition manufacturing from China to the U.S. The offering is made under an effective SEC registration statement.
NanoVibronix, Inc. (NASDAQ: NAOV) announced an underwriting agreement with H.C. Wainwright & Co. to sell 3,333,334 shares of common stock at $0.75 per share. The offering, expected to close around August 27, 2020, aims to raise approximately $2.5 million. The proceeds will be allocated for working capital and transitioning manufacturing from China to the United States. Additionally, the underwriter has a 30-day option to purchase up to 500,000 more shares. The offering is registered under Form S-3 with the SEC.
NanoVibronix, Inc. (NASDAQ: NAOV) has commenced shipments of its new UroShield® device to the UK. The company is collaborating with the National Institute of Clinical Evidence (NICE) to prepare for submission for official guidance, aiming to enhance access for NHS patients at risk of catheter-associated urinary tract infections (CAUTI). UroShield® is designed to prevent bacterial colonization in urinary catheters, thus reducing CAUTI rates and associated hospital stays. The company is also pursuing regulatory approvals in Australia and other markets.
NanoVibronix, Inc. (NASDAQ: NAOV) has signed a two-year exclusive distribution agreement with Ultra Pain Products, Inc. for its PainShield™ devices, effective June 22, 2020. This partnership aims to enhance access to opioid-free pain management solutions across the U.S. during the COVID-19 pandemic. The agreement stipulates the distribution of the newest PainShield model under specific pricing and order quantity requirements. The PainShield ultrasound device promises effective pain relief and soft tissue healing, catering to both home and clinical usage.